Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NPX267 |
| Synonyms | |
| Therapy Description |
NPX267 is a monoclonal antibody targeting KIR3DL3, which potentially blocks HHLA2 binding and leads to enhanced antitumor immune response (J Immunother Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0489). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NPX267 | NPX-267|NPX 267 | NPX267 is a monoclonal antibody targeting KIR3DL3, which potentially blocks HHLA2 binding and leads to enhanced antitumor immune response (J Immunother Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0489). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Suspended | USA | 0 |